Posted On: 04/02/2015 10:35:29 AM
Post# of 30066
8-K out.
http://www.sec.gov/Archives/edgar/data/142481...431_8k.htm
http://www.sec.gov/Archives/edgar/data/142481...431_8k.htm
Quote:
On March 19, 2015, Amarantus Bioscience Holdings, Inc. received a positive opinion for granting an orphan drug designation (ODD) application for human recombinant mesencephalic astrocyte derived neurotrophic factor for the treatment of retinitis pigmentosa from the European Medicines Agency (EMA). The EMA has forwarded its recommendation to the European Commission, which is expected to make a final decision regarding granting the ODD in the next several weeks.
(0)
(0)
